Table 2.
Overall survival |
Time to progression |
|||
Factor | HR (95% CI) | P† | HR (95% CI) | P† |
Treatment group | ||||
AE-941 vs placebo | 0.95 (0.75 to 1.20) | .65 | 1.06 (0.81 to 1.38) | .70 |
Stage | ||||
IIIB vs IIIA | 1.13 (0.89 to 1.43) | .31 | 1.05 (0.80 to 1.39) | .72 |
Chemotherapy regimen | ||||
Carboplatin vs cisplatin | 1.20 (0.94 to 1.52) | .14 | 1.17 (0.89 to 1.55) | .27 |
Sex | ||||
Male vs female | 1.04 (0.82 to 1.32) | .76 | 1.31 (0.98 to 1.74) | .07 |
Multivariable Cox proportional hazards model adjusted for treatment group, stage, chemotherapy regimen, and sex. CI = confidence interval; HR = hazard ratio.
P values (two-sided) were calculated using the Wald test under the Cox proportional hazards model.